Eton Pharma officer granted 10,000 RSUs

Krempa David reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Krempa David reported acquisition or exercise transactions in this Form 4 filing.

Eton Pharmaceuticals Chief Business Officer David Krempa received a grant of 10,000 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Eton common stock. These RSUs vest in four equal annual installments starting on June 26, 2027, as long as he remains employed on each vesting date.

Following this award, Krempa directly holds a reported total of 96,829 derivative-based shares tied to Eton common stock. This filing reflects a compensation-related equity grant rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Krempa David

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	10,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 96,829 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
2. F2. The restricted stock units vest in four equal annual installments beginning June 26, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

Key Figures

RSU grant size: 10,000 restricted stock units Underlying common shares: 10,000 shares Post-grant derivative holdings: 96,829 shares +1 more

4 metrics

RSU grant size 10,000 restricted stock units Grant of RSUs to Chief Business Officer

Underlying common shares 10,000 shares Each RSU equals one share of common stock

Post-grant derivative holdings 96,829 shares Total derivative-based shares following transaction

Vesting start date June 26, 2027 First of four equal annual RSU vesting dates

Key Terms

Restricted Stock Units, contingent right, vest in four equal annual installments, derivative

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"represents a contingent right to receive one share of ETON Common Stock"

vest in four equal annual installments financial

"The restricted stock units vest in four equal annual installments"

derivative financial

"transaction_type": "derivative""

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Eton Pharmaceuticals (ETON) disclose in this Form 4 for David Krempa?

Eton Pharmaceuticals reported that Chief Business Officer David Krempa received 10,000 restricted stock units as a compensation grant. Each RSU converts into one share of common stock if service-based vesting conditions are met over the multi-year schedule.

How many restricted stock units did Eton’s David Krempa receive?

David Krempa received a grant of 10,000 restricted stock units. These units give him the right to receive 10,000 shares of Eton common stock if he satisfies the time-based vesting conditions over the four-year vesting period.

What is the vesting schedule for David Krempa’s 10,000 ETON restricted stock units?

The 10,000 restricted stock units vest in four equal annual installments beginning June 26, 2027. Vesting on each date is contingent on Krempa continuing to be employed by Eton Pharmaceuticals at the relevant annual vesting date.

Did David Krempa buy or sell Eton Pharmaceuticals shares in this Form 4?

The Form 4 shows an acquisition via a grant of 10,000 restricted stock units, not an open-market trade. It is classified as a grant, award, or other acquisition, reflecting equity-based compensation rather than a discretionary stock purchase or sale.

How many Eton-related derivative shares does David Krempa hold after this RSU grant?

After the RSU grant, the filing reports that David Krempa holds 96,829 derivative-based shares tied to Eton common stock. This figure reflects his derivative holdings following the 10,000 restricted stock unit award reported in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krempa David

(Last) (First) (Middle)

C/O ETON PHARMACEUTICALS, INC.

21925 W. FIELD PARKWAY, SUITE 235

(Street)

DEERPARK ILLINOIS 60010-7208

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/26/2026		A		10,000		(2)	(2)	Common Stock	10,000	$0	96,829	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.

2. The restricted stock units vest in four equal annual installments beginning June 26, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

Remarks:

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.

	/s/ Judith Matthews	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)